Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
91.46 CHF | -0.62% | -2.56% | +7.80% |
05-27 | Novartis: positive phase III results in C3G | CF |
05-27 | Novartis: presented results for kidney disease | CF |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.80% | 205B | |
+38.51% | 727B | |
+32.20% | 594B | |
-6.23% | 354B | |
+18.78% | 328B | |
+1.35% | 277B | |
+14.98% | 243B | |
-6.05% | 203B | |
+6.19% | 164B | |
+0.31% | 164B |
- Stock Market
- Equities
- NOVN Stock
- News Novartis AG
- Novartis : Mulls Swiss Plant Closure On Demand Shortage